Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Juno acquired by Celgene for $9Billion following Gilead acquisition of Kite Pharma for 12.9 Billion

Reporter: Aviva Lev-Ari, PhD, RN

UPDATED on 2/5/2018

Hans Bishop gets a $287M payday as Juno execs see windfall fortunes — with a $922M payoff for Arch

by john carroll — on February 5, 2018 05:47 AM EST
Updated: 05:48 AM

https://endpts.com/hans-bishop-gets-a-287m-payday-as-juno-execs-see-windfall-fortunes-with-a-922m-payoff-for-arch/?utm_medium=email&utm_campaign=Monday%20February%205%202018&utm_content=Monday%20February%205%202018+CID_aecea465e79bcafc58b92d3615dfacda&utm_source=ENDPOINTS%20emails&utm_term=Hans%20Bishop%20gets%20a%20287M%20payday%20as%20Juno%20execs%20see%20windfall%20fortunes%20%20with%20a%20922M%20payoff%20for%20Arch

Anatomy of a $9B buyout: Celgene’s quick turn from Juno’s close collaborator to new owner

 john carroll — on February 5, 2018 05:50 AM EST

https://endpts.com/anatomy-of-a-9b-buyout-celgenes-quick-turn-from-junos-close-collaborator-to-new-owner/?utm_medium=email&utm_campaign=Monday%20February%205%202018&utm_content=Monday%20February%205%202018+CID_aecea465e79bcafc58b92d3615dfacda&utm_source=ENDPOINTS%20emails&utm_term=Anatomy%20of%20a%209B%20buyout%20Celgenes%20quick%20turn%20from%20Junos%20close%20collaborator%20to%20new%20owner

Other related articles on JUNO published in this Open Access Online Scientific Journal include the following:

Anatomy of a $9B buyout: Celgene’s quick turn from Juno’s close collaborator to new owner

https://pharmaceuticalintelligence.com/2018/02/05/anatomy-of-a-9b-buyout-celgenes-quick-turn-from-junos-close-collaborator-to-new-owner/

Juno Therapeutics to Resume JCAR015 Phase II ROCKET Trial AND Acquires privately held Boston, MA-based RedoxTherapies

https://pharmaceuticalintelligence.com/2016/07/14/juno-therapeutics-to-resume-jcar015-phase-ii-rocket-trial-and-acquires-privately-held-boston-ma-based-redoxtherapies/

What does this mean for Immunotherapy? FDA put a temporary hold on Juno’s JCAR015, Three Death of Celebral Edema in CAR-T Clinical Trial and Kite Pharma announced Phase II portion of its CAR-T ZUMA-1 trial

https://pharmaceuticalintelligence.com/2016/07/09/what-does-this-mean-for-immunotherapy-fda-put-a-temporary-hold-on-jcar015-three-death-of-celebral-edema-in-car-t-clinical-trial-and-kite-pharma-announced-phase-ii-portion-of-its-car-t-zuma-1-trial/

Juno Acquires AbVitro for $125M: high-throughput and single-cell sequencing capabilities for Immune-Oncology Drug Discovery

https://pharmaceuticalintelligence.com/2016/01/12/juno-acquires-abvitro-for-125m-high-throughput-and-single-cell-sequencing-capabilities-for-immune-oncology-drug-discovery/

Juno’s approach eradicated cancer cells in 10 of 12 leukemia patients, indicating potential to transform the standard of care in oncology

https://pharmaceuticalintelligence.com/2014/01/14/junos-approach-eradicated-cancer-cells-in-10-of-12-leukemia-patients-indicating-potential-to-transform-the-standard-of-care-in-oncology/

Economic Potential of a Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent) versus a Cancer Drug in Clinical Trials: CAR-T as a Case in Point, developed by Kite Pharma, under Arie Belldegrun, CEO, acquired by Gilead for $11.9 billion, 8/2017.

https://pharmaceuticalintelligence.com/2017/10/04/economic-potential-of-a-drug-invention-prof-zelig-eshhar-weitzman-institute-registered-the-patent-versus-a-cancer-drug-in-clinical-trials-car-t-as-a-case-in-point-developed-by-kite-pharma-unde/